LON:HCM Hutchison China MediTech Share Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hutchison China MediTech Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 528 +10.00 (+1.93 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range 499Now: GBX 528▼ 52850-Day Range 400MA: GBX 481.24▼ 52152-Week Range 249.10Now: GBX 528▼ 526Volume173,629 shsAverage Volume82,980 shsMarket Capitalization£3.75 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Bai Yun Shan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Central, Hong Kong.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingHutchison China MediTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 360, Hutchison China MediTech has a forecasted downside of 31.8% from its current price of GBX 528.Amount of Analyst CoverageHutchison China MediTech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesHutchison China MediTech has received 194 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHutchison China MediTech has received 107 “underperform” votes. (Add your “underperform” vote.)Community SentimentHutchison China MediTech has received 64.45% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote “Outperform” if you believe HCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHutchison China MediTech does not currently pay a dividend.Dividend GrowthHutchison China MediTech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hutchison China MediTech insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hutchison China MediTech is -32.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHutchison China MediTech has a P/B Ratio of 10.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.84 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorN/A Current SymbolLON:HCM Previous Symbol CUSIPN/A CIKN/A Webwww.chi-med.com Phone+85221213888Debt Debt-to-Equity Ratio9.07 Current Ratio3.14 Quick Ratio3.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£209.46 million Price / Sales17.91 Cash FlowGBX 41.53 per share Price / Cash Flow12.71 Book ValueGBX 49.80 per share Price / Book10.60Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees853 Outstanding Shares710,595,008Market Cap£3.75 billion Next Earnings DateN/A OptionableNot Optionable GBX 528 +10.00 (+1.93 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HCM News and Ratings via Email Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Hutchison China MediTech (LON:HCM) Frequently Asked Questions How has Hutchison China MediTech's stock been impacted by COVID-19? Hutchison China MediTech's stock was trading at GBX 348 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HCM shares have increased by 51.7% and is now trading at GBX 528. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Hutchison China MediTech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hutchison China MediTech in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hutchison China MediTech. What price target have analysts set for HCM? 2 brokerages have issued 1-year price targets for Hutchison China MediTech's stock. Their forecasts range from GBX 360 to GBX 360. On average, they anticipate Hutchison China MediTech's stock price to reach GBX 360 in the next twelve months. This suggests that the stock has a possible downside of 31.8%. View analysts' price targets for Hutchison China MediTech. Who are some of Hutchison China MediTech's key competitors? Some companies that are related to Hutchison China MediTech include Dechra Pharmaceuticals (DPH), Vectura Group (VEC), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), NanoViricides (NNVC), Futura Medical (FUM), Sareum (SAR), Cathay International (CTI), Avivagen (VIV), China Pharma (CPHI), N4 Pharma (N4P), Antisense Therapeutics (ANP) and Bayer (BAYN). View all competitors. What other stocks do shareholders of Hutchison China MediTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hutchison China MediTech investors own include Intelsat (I), Associated British Foods (ABF), Fossil Group (FOSL), Chaarat Gold (CGH), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU). Who are Hutchison China MediTech's key executives? Hutchison China MediTech's management team includes the following people: Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 68, Pay $80k)Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 54, Pay $1.44M)Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 53, Pay $769.68k)Dr. Wei-Guo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 63, Pay $1.13M)Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 68, Pay $70k) What is Hutchison China MediTech's stock symbol? Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM." How do I buy shares of Hutchison China MediTech? Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Hutchison China MediTech's stock price today? One share of HCM stock can currently be purchased for approximately GBX 528. How big of a company is Hutchison China MediTech? Hutchison China MediTech has a market capitalization of £3.75 billion and generates £209.46 million in revenue each year. Hutchison China MediTech employs 853 workers across the globe. What is Hutchison China MediTech's official website? The official website for Hutchison China MediTech is www.chi-med.com. How can I contact Hutchison China MediTech? The company can be reached via phone at +85221213888. This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
